APUS

Apimeds Pharmaceuticals US Inc

3.22

Oct 02 • 3:59 PM ET -0.88 (-21.46%)

3.20

Aftermarket • 7:41 PM ET -0.02 (-0.62%)

Healthcare Drug Manufacturers - Specialty & Generic USA Nano AMEX

Oct 02, 8:31 PMNo clear catalyst identified for APUS 21% regular-hours drop from the open

Peers: AYTU TXMD CPHI RMTI BGM CTOR SCYX CPIX DERM SCLX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	4.86M
Enterprise Value	11.15M
Income	-58.17M
Sales	0.00M
Book/sh	70.54
Cash/sh	5.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	May 09, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.05
P/C	0.59
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.51
Current Ratio	0.51
Debt/Eq	0.14
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-36.71
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-108.46% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-1063.72%
Sales Y/Y TTM	-
EPS Q/Q	-456.18%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	62.68%
Insider Trans	0.00%
Inst Own	2.82%
Inst Trans	-
ROA	-84.20%
ROE	-100.13%
ROIC	-54.59%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.27%
SMA50	-19.65%
SMA200	-74.81%
Trades

Shs Outstand	1.51M
Shs Float	0.56M
Short Float	1.85%
Short Ratio	0.00
Short Interest	0.01M
52W High	59.70 -94.61%
52W Low	1.51 113.25%
Volatility	23.95% 23.49%
ATR (14)	1.17
RSI (14)	46.45
Beta	-0.25
Rel Volume	0.07
Avg Volume	2.09M
Volume	138,735

Perf Week	-55.59%
Perf Month	22.43%
Perf Quarter	-62.56%
Perf Half Y	-82.87%
Perf YTD	-80.37%
Perf Year	-81.28%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	4.10
Price	3.22
Change %	-21.46%

Sep-29-26 08:30AM	MindWave Innovations Expands U.S. Commercial Footprint with Second Agreement to Build and Operate FlashChain for New York-Based Flash Sports & Media (GlobeNewswire) -21.44%
Sep-24-26 08:30AM	MindWave Innovations Signs Agreement to Build and Operate AQUAEChain, a Platform for Insured ALCI Credits (GlobeNewswire) +114.85%
Aug-03-26 09:00AM	NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange (GlobeNewswire) -5.83%
Jul-28-26 08:30AM	MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October (GlobeNewswire) +27.19%
Jul-07-26 09:30PM	Inside the ICE House x Las Vegas: MindWave Innovations CEO Dr. Vin Menon (NYSE) -13.66%

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Matawan, NJ.

PresidentMr. Erik C. Emerson

Chief Financial OfficerMr. Erick J. Frim

Founder & Co-CEODr. Vinod Menon

Co-CEO & DirectorMr. Sungjoon Chae

Chief Operating OfficerCaptain Sandeep Singh Yadav

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APUS

Apimeds Pharmaceuticals US Inc

Upgrade your Finviz experience